NASDAQ:ACST

Acasti Pharma Stock Forecast, Price & News

$0.46

0.00 (0.00 %)

(As of 07/30/2021 12:00 AM ET)

Add

Compare

Today's Range

$0.45

▼

$0.47

50-Day Range

$0.46

▼

$0.61

52-Week Range

$0.17

▼

$1.22

Volume3.21 million shs

Average Volume6.98 million shs

Market Capitalization$95.13 million

P/E RatioN/A

Dividend YieldN/A

Beta1.95

30 days | 90 days | 365 days | Advanced Chart

Receive ACST News and Ratings via Email

Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter.

About Acasti Pharma

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre, an omega-3 phospholipid therapeutic to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Reminder: Acasti Pharma to Host Conference Call on August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics
July 29, 2021 | finance.yahoo.com

Acasti Pharma, Inc. Class A Common Stock (ACST)
July 27, 2021 | nasdaq.com

Acasti Pharma Schedules Conference Call for August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics
July 23, 2021 | finance.yahoo.com

Acasti Pharma (NASDAQ:ACST) Stock Price Passes Above 200-Day Moving Average of $0.00
July 10, 2021 | americanbankingnews.com

Acasti Pharma Inc.'s (CVE:ACST) Shift From Loss To Profit
June 24, 2021 | finance.yahoo.com

Acasti Pharma Provides Fiscal 2021 Year-End Business Update
June 22, 2021 | finance.yahoo.com

Acasti Intends to Request Hearing Before Nasdaq Panel to Present Plan of Compliance
May 17, 2021 | finance.yahoo.com

ACASTI PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Acasti Pharma Inc. - ACST
May 12, 2021 | finance.yahoo.com

Acasti up on Buying Grace
May 10, 2021 | baystreet.ca

Acasti Pharma unveils proposal to buy Grace Therapeutics and its portfolio of drug candidates in all-stock deal
May 7, 2021 | proactiveinvestors.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACST
Previous Symbol
CUSIPN/A
CIK1444192
Webwww.acastipharma.com
Phone450 687 2262
Employees32
Year FoundedN/A

Sales & Book Value

Annual Sales$200,000.00
Price / Sales475.63
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.27 per share
Price / Book1.69

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares208,380,000
Market Cap$95.13 million
Next Earnings Date8/12/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.56 out of 5 stars

Medical Sector

1074th out of 2,220 stocks

Pharmaceutical Preparations Industry

505th out of 869 stocks

3.1 Analyst's Opinion

Consensus Rating
Acasti Pharma has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $1.75, Acasti Pharma has a forecasted upside of 283.4% from its current price of $0.46.
Amount of Analyst Coverage
Acasti Pharma has received no research coverage in the past 90 days.

4.7 Community Rank

Outperform Votes
Acasti Pharma has received 305 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Acasti Pharma has received 126 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Acasti Pharma has received 70.77% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Acasti Pharma and other stocks. Vote “Outperform” if you believe ACST will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ACST will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Acasti Pharma does not currently pay a dividend.
Dividend Growth
Acasti Pharma does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Acasti Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.70% of the stock of Acasti Pharma is held by insiders.
Percentage Held by Institutions
Only 1.07% of the stock of Acasti Pharma is held by institutions.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Acasti Pharma is -3.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Acasti Pharma is -3.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Acasti Pharma has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Acasti Pharma (NASDAQ:ACST) Frequently Asked Questions

Is Acasti Pharma a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acasti Pharma in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Acasti Pharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACST, but not buy additional shares or sell existing shares.
View analyst ratings for Acasti Pharma or view top-rated stocks.

What stocks does MarketBeat like better than Acasti Pharma?

Wall Street analysts have given Acasti Pharma a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Acasti Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Acasti Pharma?

Acasti Pharma saw a decrease in short interest in June. As of June 15th, there was short interest totaling 3,170,000 shares, a decrease of 31.2% from the May 31st total of 4,610,000 shares. Based on an average trading volume of 13,100,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 1.5% of the company's shares are sold short.
View Acasti Pharma's Short Interest.

When is Acasti Pharma's next earnings date?

Acasti Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Acasti Pharma.

How were Acasti Pharma's earnings last quarter?

Acasti Pharma Inc. (NASDAQ:ACST) announced its quarterly earnings results on Tuesday, June, 22nd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter.
View Acasti Pharma's earnings history.

How has Acasti Pharma's stock price been impacted by Coronavirus (COVID-19)?

Acasti Pharma's stock was trading at $0.3849 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ACST stock has increased by 18.6% and is now trading at $0.4565.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ACST?

4 equities research analysts have issued 12-month target prices for Acasti Pharma's stock. Their forecasts range from $0.50 to $3.00. On average, they expect Acasti Pharma's share price to reach $1.75 in the next year. This suggests a possible upside of 283.4% from the stock's current price.
View analysts' price targets for Acasti Pharma or view top-rated stocks among Wall Street analysts.

Who are Acasti Pharma's key executives?

Acasti Pharma's management team includes the following people:

Ms. Janelle D'Alvise, Pres, CEO, Corp. Sec. & Director (Age 65, Pay $428.04k)
Dr. Pierre Lemieux, Co-Founder, COO & Chief Scientific Officer (Age 56, Pay $276.38k)
Mr. Brian D. Ford CPA, CA, Chief Financial Officer (Age 62, Pay $364.82k)

Who are some of Acasti Pharma's key competitors?

Some companies that are related to Acasti Pharma include Biomea Fusion (BMEA), Vera Therapeutics (VERA), Alzamend Neuro (ALZN), Akouos (AKUS), BeyondSpring (BYSI), BioDelivery Sciences International (BDSI), Amryt Pharma (AMYT), Athersys (ATHX), XOMA (XOMA), Verona Pharma (VRNA), Homology Medicines (FIXX), Atossa Therapeutics (ATOS), CytomX Therapeutics (CTMX), Nature's Sunshine Products (NATR) and Altimmune (ALT).
View all of ACST's competitors.

What other stocks do shareholders of Acasti Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Matinas BioPharma (MTNB), SCYNEXIS (SCYX), Outlook Therapeutics (OTLK), Bionano Genomics (BNGO), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Heat Biologics (HTBX), KushCo (KSHB), Miragen Therapeutics (MGEN) and Aeterna Zentaris (AEZS).

What is Acasti Pharma's stock symbol?

Acasti Pharma trades on the NASDAQ under the ticker symbol "ACST."

How do I buy shares of Acasti Pharma?

Shares of ACST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acasti Pharma's stock price today?

One share of ACST stock can currently be purchased for approximately $0.46.

How much money does Acasti Pharma make?

Acasti Pharma has a market capitalization of $95.13 million and generates $200,000.00 in revenue each year.

How many employees does Acasti Pharma have?

Acasti Pharma employs 32 workers across the globe.

What is Acasti Pharma's official website?

The official website for Acasti Pharma is www.acastipharma.com.

Where are Acasti Pharma's headquarters?

Acasti Pharma is headquartered at 3009 BOUL. DE LA CONCORDE EAST SUITE 102, LAVAL A8, H7E 2B5.

How can I contact Acasti Pharma?

Acasti Pharma's mailing address is 3009 BOUL. DE LA CONCORDE EAST SUITE 102, LAVAL A8, H7E 2B5. The biopharmaceutical company can be reached via phone at 450 687 2262 or via email at [email protected]

This page was last updated on 8/1/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here